Real-world data on benralizumab for severe asthma: what happens outside clinical trials?
NCT ID NCT07218172
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks back at medical records of 197 adults in Israel who started benralizumab for severe asthma between 2019 and 2024. Researchers will count how many asthma attacks (exacerbations) patients had before and after starting the drug. The goal is to see how well benralizumab works in everyday practice, not just in controlled studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
benralizumab
What this could lead to
If successful, this study could provide real-world evidence on how well benralizumab controls severe asthma in routine practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors and cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE EOSINOPHILIC ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Tel Aviv, Israel